Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Registry comparison of ATG and alemtuzumab for in vivo T-cell depletion in GVHD prophylaxis among unrelated-donor allo-HCT recipients with AML and intermediate-intensity conditioning, on behalf of the EBMT Acute Leukemia Working Party

  • By

  • Jesús Duque-Afonso

  • Jürgen Finke

  • Allain-Thibeault Ferhat

  • Jacques-Emmanuel Galimard

  • Francesca Kinsella

  • Deborah Richardson

  • Friedrich Stölzel

  • Eleni Tholouli

  • Caroline Besley

  • Matthias Eder

  • Emma Nicholson

  • Robert Zeiser

  • Adrian Bloor

  • Charles Crawley

  • Katherine Clesham

  • Jennifer Byrne

  • Patrick Medd

  • Elisa Sala

  • Caroline Pabst

  • Jan Vydra

  • Eva Maria Wagner-Drouet

  • Alain Gadisseur

  • Alexandros Spyridonidis

  • Eolia Brissot

  • Arnon Nagler

  • Mohamad Mohty

  • Fabio Ciceri

  • October 23, 2026

Share

Clinical Scorecard: Correction: Registry comparison of ATG and alemtuzumab for in vivo T-cell depletion in GVHD prophylaxis

At a Glance

CategoryDetail
ConditionCorrection notice concerning an author-name error in a Bone Marrow Transplantation article
Key MechanismsNot stated in the correction notice.
Target PopulationNot stated in the correction notice.
Care SettingPublication record

Key Highlights

  • The correction was published online on 10 September 2026.
  • The correction concerns the article in Bone Marrow Transplantation, DOI 10.1038/s41409-026-03016-7.
  • The author name ‘Allain-Thibeault Ferhat’ was erroneously published as ‘Thibeault Ferhat-Berland’.
  • A correction has been issued for the article.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not stated in the correction notice.

          The correction notice reports an author-name error and provides no treatment findings.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

            • by Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Patrick Medd, Elisa Sala, Caroline Pabst, Jan Vydra, Eva Maria Wagner-Drouet, Alain Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty, Fabio Ciceri

            • October 23, 2026

            Related Content

            Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients

            2026 ASCO Breast Cancer Highlights: SENOMAC

            Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

            • October 15, 2026

            • 1 min
            The Evidence-Based Cancer Control Programs website – a strategy for disseminating effective interventions